Epigenetic agents in combined anticancer therapy
Language English Country England, Great Britain Media print-electronic
Document type Journal Article, Research Support, Non-U.S. Gov't, Review
PubMed
29676175
DOI
10.4155/fmc-2017-0203
Knihovny.cz E-resources
- Keywords
- anticancer treatment, combination therapy, epigenetic agents,
- MeSH
- DNA Modification Methylases pharmacology MeSH
- Epigenesis, Genetic drug effects MeSH
- Histone Acetyltransferases antagonists & inhibitors MeSH
- Histone Demethylases antagonists & inhibitors MeSH
- Histone Methyltransferases antagonists & inhibitors MeSH
- Histone Deacetylase Inhibitors pharmacology therapeutic use MeSH
- Combined Modality Therapy methods MeSH
- Humans MeSH
- DNA Methylation drug effects MeSH
- Neoplasms drug therapy genetics therapy MeSH
- Drug Discovery methods MeSH
- Antineoplastic Agents pharmacology therapeutic use MeSH
- Gene Expression Regulation, Neoplastic drug effects MeSH
- Animals MeSH
- Check Tag
- Humans MeSH
- Animals MeSH
- Publication type
- Journal Article MeSH
- Research Support, Non-U.S. Gov't MeSH
- Review MeSH
- Names of Substances
- DNA Modification Methylases MeSH
- Histone Acetyltransferases MeSH
- Histone Demethylases MeSH
- Histone Methyltransferases MeSH
- Histone Deacetylase Inhibitors MeSH
- Antineoplastic Agents MeSH
In the last decade, epigenetic drugs (such as inhibitors of DNA methyltransferases and histone deacetylases) have been intensively used for cancer treatment. Their applications have shown high anticancer effectivity and tolerable side effects. However, they are unfortunately not effective in the treatment of some types and phenotypes of cancers. Nevertheless, several studies have demonstrated that problems of drug efficacy can be overcome through the combined application of therapeutic modulates. Therefore, combined applications of epigenetic agents with chemotherapy, radiation therapy, immunotherapy, oncolytic virotherapy and hyperthermia have been presented. This review summarizes and discusses the general principles of this approach, as introduced and supported by numerous examples. In addition, predictions of the future potential applications of this methodology are included.
1st Faculty of Medicine Charles University Prague Kateřinská 32 121 08 Prague 2 Czech Republic
BIOCEV 1st Faculty of Medicine Charles University 252 50 Vestec Czech Republic
References provided by Crossref.org
Targeting of the Mitochondrial TET1 Protein by Pyrrolo[3,2-b]pyrrole Chelators
